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64.The Antiviral Effect of a Novel Inhibitor of Influenza Virus Hemagglutinin on Influenza A (H5N1) Virus*Svetlana Rak*^1^, Elena Goncharova^1^, Alexander Chinarev^2^, Alexander Tuzikov^2^, Nicolai Bovin^2^, Alexander Ryzhikov^11^FSRI SRC of Virology and Biotechnology Vector, Koltsovo, Russia; ^2^Shemyakin Institute of Bioorganic Chemistry, Moscow, Russia  65.*In Vitro* Anti-Influenza Virus Effect of a Protease Inhibitor from a *Streptomyces* Strain*Julia Serkedjieva*^1^, Lidia Angelova-Duleva^1,2^, Iskra Ivanova^21^Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria; ^2^Department of Microbiology, Sofia University, Sofia, Bulgaria  66.Protective Effect of a Fungal Superoxide Dismutase Combined with a Plant Polyphenol Extract and Rimantadine Hydrochloride in the Murine Experimental Influenza Virus Infection*Julia Serkedjieva*, Maria AngelovaInstitute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria  67.Discovery of New Inhibitors of the Influenza H5N1 Virus*William Severson*^1^, Xi Chen^1^, Joseph Maddry^1^, Yong-Kyu Chu^1^, Colleen Jonsson^1^, Alexis Mcbrayer^1^, Ronald Tapp^1^, Donald Smee^2^, Clinton Maddox^1^, Subramaniam Ananthan^1^, James Noah^1^, Leland Black^1^, Blake Moore^1^, Melinda Sosa^1^, Lucile White^1^, Lynn Rasmussen^11^Southern Research Institute, Drug Discovery Division, Birmingham, AL, United States; ^2^Institute For Antiviral Research, Logan, UT, United States  68.Rimantadine and Oseltamivir Combination Effects in a Therapeutic Course of Application Against Influenza A (H3N2) in Mice*Lora Simeonova*, Galina Gegova, Angel S. GalabovInstitute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria  69.Combination of Neuraminidase Inhibitors with T-705 for Treating Influenza Virus Infections in Cell Culture and in Mice*Donald Smee*^1^, Min-Hui Wong^1^, Kevin Bailey^1^, John Morrey^1^, Masako Maekawa^2^, Kazumi Takahashi^2^, Yousuke Furuta^21^Utah State University, Logan, UT, United States; ^2^Toyama Chemical Co., Ltd., Toyama, Japan  70.High-Throughput Screening of Protease Inhibitor Libraries Using a Novel Dual Pseudotype-based Assay for SARS-CoV Entry*Yanchen Zhou*, Kai Lu, Juliet Agudelo, Graham SimmonsBlood Systems Research Institute, and University of California, San Francisco, San Francisco, CA, United States  71.Pichinde Virus Induces Endothelial Cell Monolayer Permeability Through the Production of Nitric OxideRebecca Brocato, Thomas VossTulane School of Medicine, Department of Microbiology and Immunology, New Orleans, LA, United States  72.Novel Small Molecule Inhibitors of Dengue Virus Replication*Chelsea Byrd*, Jessica Page, Chris Harver, Doug Grosenbach, Aklile Berhanu, Dennis Hruby, Robert JordanSIGA Technologies, Corvallis, OR, United States  73.Escaping Development of Drug-Resistant Mutants: Basis for Effective Chemotherapy of Enterovirus Infections*Angel S. Galabov*^1^, Ralitsa Vassileva-Pencheva^1^, Ivanka Nikolova^1^, Boris Atanassov^21^Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria; ^2^Institute of Organic Chemistry, Bulg. Acad. Sci., Sofia, Bulgaria  74.Escaping Development of Drug-Resistant Mutants: Basis for Effective Chemotherapy of Enterovirus Infections*Angel S. Galabov*^1^, Ralitsa Vassileva-Pencheva^1^, Ivanka Nikolova^1^, Boris Atanasov^21^The Stephan Angeloff Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria; ^2^Institute of Organic Chemistry, Bulg. Acad. Sci., Sofia, Bulgaria  75.Arenaviral Inhibitory Activity of MY-24---A Novel Aristeromycin Derivative*Brain Gowen*^1^, Kie-Hoon Jung^1^, Wei Ye^2^, Min-Hui Wang^1^, Deanna Larson^1^, Donald Smee^1^, John Morrey^1^, Stewart Schneller^21^Institute For Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT, United States; ^2^Chemistry & Biochemistry Department, Auburn University, Auburn, AL, United States  76.Pyrazine Derivative Treatment of Phleboviral Infection in Cell Culture and Rodent Model Systems*Brian Gowen*^1^, Min-Hui Wong^1^, Kie-Hoon Jung^1^, Donald Smee^1^, John Morrey^1^, Yousuke Furuta^21^Utah State University, Logan, UT, United States; ^2^Research Laboratories, Toyama Chemical Company, Ltd., Toyama, Japan  77.FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection*Michael Kinch*^1^, Abdul Yunus^1^, Hanwen Mao^1^, Calli Lear^2^, Guangxiang Luo^3^, Michael Murray^4^, Zhuhui Huang^4^, Zena Fesseha^1^, Hanson Chen^1^, Gene Olinger^2^, Michael Goldblatt^11^Functional Genetics, Inc., Gaithersburg, MD, United States; ^2^United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, United States; ^3^Department of Microbiology Immunology and Molecular Genetics, Lexington, KY, United States; ^4^Hepatitis Research Program, Frederick, MD, United States  78.Derivatives of Tunicamycin as Effective Inhibitors of Classical Swine Fever Virus*Ewelina Krol*^1^, Ilona Wandzik^3^, Boguslaw Szewczyk^1^, Grzegorz Grynkiewicz^2^, Wieslaw Szeja^31^Department of Molecular Virology, University of Gdansk, Gdansk, Poland; ^2^Pharmaceutical Institute, Warsaw, Poland; ^3^Silesian Technical University, Gliwice, Poland  79.Anti-Picornavirus Activity and other Antiviral Activity of Sulfated Exopolysaccharide from the Marine Microalga *Gyrodinium impudicum* Strain KG03*Chong-Kyo Lee*^1^, Hae Soo Kim^1^, Ju Ryung Nam^1^, Myung-Jin Lee^1^, Joung-Han Yim^2^, Hong Kum Lee^2^, Erik De Clercq^31^Pharmacology Research Center, Korea Research Institute of Chemical Technology (KRICT), 305-600 Daejeon, Korea; ^2^Polar Biocenter, Korea Polar Research Institute (KOPRI), 406-840 Incheon, Korea; ^3^Rega Institute For Medical Research, K.U.Leuven, 3000 Leuven, Belgium  80.Assay Development for Antiviral Drug Efficacy Evaluation against Dengue Virus*Qianjun Li*University of Alabama At Birmingham, Birmingham, AL, United States  81.Structural Basis of the Disoxaril Resistance and Dependence of Coxsackievirus B1*Ivanka Nikolova*^1^, Angel S. Galabov^1^, Rumena Petkova^2^, Stoyan Chakarov^3^, Boris Atanasov^41^Institute of Microbiology, Bulg. Acad. Sci., Sofia, Bulgaria; ^2^2Scientific Technological Service, Ltd., Sofia, Bulgaria; ^3^3Department of Biochemistry, Sofia University, Sofia, Bulgaria; ^4^Institute of Organic Chemistry, Bulg. Acad. Sci., Sofia, Bulgaria  82.Anti-Adenoviral Activity of 6-Azanucleoside Analogues*Lidiya Nosach*^1^, Olga Povnitsa^1^, Inna Alexeeva^2^, Larisa Palchikovska^2^, Nadezhda Nesterova^11^Institute of Microbiol. & Virol., NAS of Ukraine, Kiev, Ukraine; ^2^Institute of Mol. Biol. & Genetic NAS of Ukraine, Kiev, Ukraine  83.Antiviral Activity of Octadecyloxypropyl Esters of 3-Hydroxy-2-(Phosphonomethoxy)Propyl Nucleosides against Adenovirus *In VitroJ.P. Roth*^1^, T.Z. Mclean^1^, N. Valiaeva^2^, J.R. Beadle^2^, K.Y. Hostetler^2^, D.L. Barnard^11^Institute For Antiviral Research, Utah State University, Logan, UT, United States; ^2^Division of Infectious Disease, University of California, San Diego, La Jolla, CA, United States  84.Indole Derivatives are Potent Inhibitors of HIV Integrase*Periyasamy Selvam*^1^, Kasthuraiah Maddali^2^, Yves Pommier^21^Dept. of Medicinal Chemistry, Amrita School of Pharmacy, Kochi 26, India; ^2^Laboratory of Molecular Pharmacology, Centre For Cancer Research, NCI, NIH, Bethesda, WA, United States  85.The Antiproliferative Effects of Octadecyloxyethyl-phosphonomethoxyethylguanine (Ode-Pmeg) on the Growth of Human Papilloma Virus Positive Cervical Carcinoma (ME-180) Cells *In Vitro* and Solid Tumors in Athymic Nude Mice*Julissa Trahan*, Kathy Aldern, Karl HostetlerUniversity of California San Diego and The Veterans Medical Research Foundation, San Diego, CA, United States  86.Antiviral Activity of Geneticin Against Dengue Virus*Xianchao Zhang*^1^, Peter Mason^2^, Edward Dubovi^3^, Alex Birk^11^Institute For Hepatitis and Virus Research, Doylestown, PA, United States; ^2^University of Texas Medical Branch, Galveston, TX, United States; ^3^Cornell University, Ithaca, NY, United States  **Tuesday, May 5, 2009**  **Oral Session 3: Retroviruses**Chairs: Jan Balzarini, Ph.D. and Ronald Swanstrom, Ph.DMediterranean East08:00--11:30 08:0087.Plenary: A Strong Dominant Negative Mutation in the HIV-1 Gag Protein Defines a New Drug Target*Ronald Swanstrom*, Ph.D.The University of North Carolina, Chapel Hill, NC, USA   08:3088.Small-molecule CCR5 Ligands that may Spare the CCR5 Function: Opportunity for New Antiviral Discovery?*Wieslaw Kazmierski*, Vanessa Muniz-Medina, Susan Danehower, Stacey Jones, Terry KenakinGlaxosmithkline, Research Triangle Park, NC, United States   08:4589.Development of Hexadecyloxypropyl Tenofovir (CMX157) for HIV: Potential for use as a Microbicide and Therapeutic*Randall Lanier*, Bernhard Lampert, Lawrence Trost, Merrick Almond, George PainterChimerix Inc, Durham, NC, United States   09:0090.Toward Unsymmetrical CADA Analogs as Novel Down-modulators of the CD4 Receptor*Violeta Demillo*^1^, Sreenivasa Anugu^1^, Kurt Vermeire^2^, Dominique Schols^2^, Thomas Bell^11^Department of Chemistry, University of Nevada, Reno, NV, United States; ^2^Rega Institute For Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium   09:15Break   09:4591.Pradimicin-S is a Highly Soluble Non-peptidic Small-size Carbohydrate-binding Antibiotic that may Qualify as a Potential Drug Lead for HIV Treatment*J. Balzarini*^1^, K. François^1^, K. Van Laethem^1^, B. Hoorelbeke^1^, J. Auwerx^1^, S. Liekens^1^, Y. Igarashi^2^, T. Oki^3^, D. Schols^11^Rega Institute For Medical Research, K.U. Leuven, B-3000 Leuven, Belgium; ^2^Biotechnology Research Center, Toyama Prefectural University, Toyama 939-0398, Japan; ^3^Shoda, Sakae, Yokohama 247-0022, Japan   10:0092.Highly Potent and Dual Acting Pyrimidinedione Inhibitors of HIV-1 Possess a High Genetic Barrier to Resistance*Robert W. Buckheit, Jr.*, Karen Watson, Tracy Hartman, Lu YangImQuest BioSciences, Inc., Frederick, MD, United States   10:1593.Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides as Potent NNRTIs*Xinyong Liu*^1^, Peng Zhan^1^, Christophe Pannecouque^2^, Erik De Clercq^21^Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012, Jinan, China; ^2^Rega Institute For Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, Leuven, Belgium   10:3094.ZNRD1 as a Host Cellular Factor Influencing HIV-1 Replication*Ester Ballana*, Jordi Senserrich, Eduardo Pauls, Josep Maria Mercader, Bonaventura Clotet, Lidia Ruiz, Jorge Gallego, Frédéric Uyttebroeck, Amalio Telenti, Angela Cuiffi, José A. EstéRetrovirology Laboratory Irsicaixa, Hospital Universitari Germans Trias I Pujol, Universitat Autònoma De Barcelona, Badalona, Spain   10:4595.CXCR4 Chemokine Receptor Antagonists from Ultra Rigid Metal Complexes Profoundly Inhibit HIV-1 Replication and also AMD3100-resistant Strains*Stephen J. Archibald*^1^, Dirk Daelemans^2^, Timothy J. Hubin^3^, Dana Huskens^2^, Dominique Schols^2^, Kristel Van Laethem^2^, Erik De Clercq^2^, Christophe Pannecouque^21^Department of Chemistry and Clinical Biosciences Institute, University of Hull, Hull, HU6 7RX, United Kingdom; ^2^Rega Institute For Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; ^3^Department of Chemistry and Physics, Southwestern Oklahoma State University, OK 73096, United States   11:0096.High-throughput *In Vitro* HIV Rev-multimerization Assay*Thomas Vercruysse*^1^, George Pavlakis^2^, Dirk Daelemans^11^Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven 3000, Belgium; ^2^Human Retrovirus Pathogenesis Section, National Cancer Institute, Frederick 21702-1201, MD, United States   11:1597.Pre-clinical Development of IQP-0410---A Highly Potent Dual-acting Agent for the Therapy of HIV-1 Infection*Nick Kaludov*, Karen Watson, Robert Buckheit, Jr.ImQuest BioSciences Inc., Frederick, MD, United States  **Clinical Symposium**Chairs: Richard Pollard, M.D. and Richard Whitley, M.D.Mediterranean East13:00--16:00  **Poster Session 2: Herpesviruses, Poxviruses, Other Antiviral Agents, Medicinal Chemistry And Topical Microbicides**Mediterranean West and Central16:00--18:00 p.m.98.Antiviral Activity of Monoterpene Components of Essential Oils Against Herpes Simplex Virus*Akram Astani*^1^, Jürgen Reichling^2^, Paul Schnitzler^11^ Department of Virology, Hygiene Institute, University of Heidelberg, Heidelberg, Germany; ^2^ Department of Biology, Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany  99.Preclinical Pharmacokinetic, Toxicokinetic and Toxicology Results for Cyclopropavir---A Promising New Agent for the Treatment of Beta- and Gamma-Herpesviruses*Terry Bowlin*^1^, Jennifer Brooks^1^, Jiri Zemlicka^21^Microbiotix, Inc., Worcester, MA, United States; ^2^Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States  100.Phenotyping Human Cytomegalovirus Drug Resistance Mutations Using a Recombinant Virus Incorporating EGFP*Meike Chevillotte*^1^, Hans A. Kestler^2^, Thomas Mertens^1^, Jens Von Einem^11^Institute of Virology, University Hospital, Ulm, Germany; ^2^Internal Medicine I, University Hospital, Ulm, Germany  101.The Effect of Human Cytomegalovirus Proteins Pul97 and Pul27 on Host Interferon Responses*Rachel Gill*, Etty Benveniste, Mark PrichardUniversity of Alabama School of Medicine, Birmingham, AL, United States  102.Mutation of the Thymidine Kinases Encoded by Herpes Simplex Virus or Vaccinia Virus can confer Resistance to 5-Iodo-4′-Thio-2′-Deoxyuridine*Emma Harden*^1^, Kathy Keith^1^, Shannon Daily^1^, Kamal Tiwari^2^, Joseph Maddry^2^, John Secrist^2^, Earl Kern^1^, Mark Prichard^11^University of Alabama School of Medicine, Birmingham, AL, United States; ^2^Southern Research Institute, Birmingham, AL, United States  103.Conserved Retinoblastoma Protein-binding Motifs in Human Cytomegalovirus UL97 Minimally Impact Viral Replication But Can Affect Susceptibility to Maribavir*Caroll Hartline*^1^, Rachel Gill^1^, Samuel Frederick^1^, Sunwen Chou^2^, Mark Prichard^11^University of Alabama School of Medicine, Birmingham, AL, United States; ^2^Oregon Health and Science University, Portland, OR, United States  104.Antiviral Activities of Nucleoside Analogs Against HSV-1 Replication in 143B Cells Expressing the Viral Tk Genes with Different Initiation Codon Sites*Chong-Kyo Lee*, Ju Ryung Nam, Myung-Jin Lee, Hae Soo KimKorea Research Institute of Chemical Technology, Daejeon, Korea, Korea  105.A Study of the Safety and Pharmacokinetics of Multiple Ascending Doses of FV-100 in Healthy Subjects*Mark Matson*^1^, Helen Pentikis^2^, Brian Boehlecke^3^, Eric Wenzel^4^, Geoff Henson^4^, Amy Morris^41^Prism Research Inc., St. Paul, MN, United States; ^2^SAJE Consulting LLC, Baltimore, MD, United States; ^3^Rho Inc., Chapel Hill, NC, United States; ^4^Inhibitex, Inc., Alpharetta, GA, United States  106.A Study of the Safety and Pharmacokinetics of Single and Multiple Doses of FV-100 in Subjects 65 years and Over.*Mark Matson*^1^, George Atiee^2^, Helen Pentikis^3^, Brian Boehlecke^4^, Eric Wenzel^5^, Amy Morris^51^Prism Research Inc., St. Paul, MN, United States; ^2^ICON Plc., San Antonio, TX, United States; ^3^SAJE Consulting LLC, Baltimore, MD, United States; ^4^Rho Inc., Chapel Hill, NC, United States; ^5^Inhibitex Inc., Alpharetta, GA, United States  107.Study of Anti Epstein-Barr Virus Activity of Novel Fluorinated Heterocyclic Nucleoside Analogues*N. Nesterova*^1^, Yu. Shermolovich^2^, S. Zagorodnya^1^, A. Golovan^1^, O. Kanishchev^2^, G. Baranova^11^Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, Kyiv, Ukraine; ^2^Institute of Organic Chemistry, NAS of Ukraine, Kyiv, Ukraine  108.Study of Anti Epstein-Barr Virus Activity of Novel Fluorinated Heterocyclic Nucleoside Analogues*N. Nesterova*^1^, Yu. Shermolovich^2^, S. Zagorodnya^1^, A. Golovan^1^, O. Kanishchev^2^, G. Baranova^11^Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, Kyiv, Ukraine; ^2^Institute of Organic Chemistry, NAS of Ukraine, Kyiv, Ukraine  109.Induction of Lytic Cytotoxicity by NF-KB Inhibitors in Epstein-Barr Virus-associated Gastric Carcinoma Cells*Paula Ordonez Suarez*^1^, Chihaya Koriyama^1^, Yoshito Eizuru^2^, Suminori Akiba^11^Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; ^2^Division of Oncogenic and Persistent Viruses, Center For Chronic Viral Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan  110.Anti-Cytomegalovirus Activity of Membranotropic Polyacidic Agents Effects *In VitroM. Pavlova*^1^, A. Serbin^2^, N. Fedorova^1^, E. Karaseva^2^, E. Klimova^1^, A. Kushch^11^Ivanovski Virology Inst., Moscow, Russia; ^2^Health RDF, Moscow, Peru  111.A Mass Spectrometry-based Method to Detect Antiviral Drug Resistance in Human Cytomegalovirus*Clara Posthuma*, Martha Van Der Beek, Caroline Van Der Blij, Willy Spaan, Louis Kroes, Eric SnijderLeiden University Medical Center, Leiden, Netherlands  112.[l]{.smallcaps}-Analogs of 1-Beta-[d]{.smallcaps}-Ribofuranosyl-2-Bromo-5,6-Dichlorobenzimidazole (BDCRB) inhibit Human Herpesvirus-6 Replication*Mark Prichard*^1^, Samuel Frederick^1^, Shannon Daily^1^, Kathy Borysko^2^, Julie Breitenbach^2^, Leroy Townsend^2^, John Drach^21^The University of Alabama School of Medicine, Birmingham, AL, United States; ^2^School of Dentistry and College of Pharmacy, University of Michigan, Ann Arbor, MI, United States  113.Comparative Efficacy of Treatment with CMX001 Versus Acyclovir in Balb/C Mice Infected with Herpes Simplex Virus*Debra Quenelle*^1^, Mark Prichard^1^, Emma Harden^1^, Deborah Collins^1^, Terri Rice^1^, George Painter^2^, Alice Robertson^2^, Earl Kern^11^University of Alabama School of Medicine, Birmingham, AL, United States; ^2^Chimerix, Inc., Durham, NC, United States  114.Compounds that Target Host Cell Enzymes Prevent Varicella-Zoster Virus Replication *In Vitro*, *Ex Vivo*, and In SCID-HU Mice*J. Rowe*, R. Greenblatt, D. Liu, J. MoffatSUNY Upstate Medical University, Syracuse, NY, United States  115.Evaluation of Octadecyloxyethyl Esters of 3-Hydroxy-2-(Phosphonomethoxy)Propyl Nucleosides against HCMV, HSV and Poxviruses*Nadejda Valiaeva*^1^, Julissa Trahan^1^, Kathy A. Keith^2^, Caroll Hartline^2^, Mark Prichard^2^, James R. Beadle^1^, Karl Y. Hostetler^11^University of California, San Diego, and The Veterans Medical Research Foundation, La Jolla, CA, United States; ^2^University of Alabama, Birmingham, AL, United States  116.Effects of Antivirals via Intratympanic Delivery in GPCMV Related Hearing Loss*Jonette Ward*^1^, Daniel Choo^1,21^Cincinnati Children\'s Hospital Medical Center, Cincinnati, OH, United States; ^2^University of Cincinnati, Cincinnati, OH, United States  117.Inhibition of Herpes Simplex Virus by Polyamines*Ira Yudovin-Farber*^1^, Irina Gurt^2^, Ronen Hope^2^, Abraham J. Domb^1^, Ehud Katz^21^Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Faculty of Medicine, Hebrew University, Jerusalem, Israel; ^2^Department of Virology, Hadassah Medical School, Hebrew University, Jerusalem, Israel  118.Characterization of Cowpox Virus (CPV) Mutants Arising under Pressure with Different Acyclic Nucleoside Phosphonates*Graciela Andrei*, Pierre Fiten, Erik De Clercq, Ghislain Opdenakker, Robert SnoeckRega Institute, Leuven, Belgium  119.Interactions between the Human Oligopeptide Transporter, HPEPT1 and Serine Side Chain-linked Cidofovir Prodrugs*Monica Sala-Rabanal*^1^, Larryn W. Peterson^2^, Michaela Serpi^2^, Ivan S. Krylov^2^, Boris A. Kashemirov^2^, Jae Seung Kim^3^, Stefanie Mitchell^3^, John M. Hilfinger^3^, Charles E. Mckenna^21^Department of Physiology, David Geffen School of Medicine, UCLA, Los Angeles, CA, United States; ^2^Department of Chemistry, University of Southern California, Los Angeles, CA, United States; ^3^TSRL, Inc., Ann Arbor, MI, United States  120.Compounds Designed to Bind Conserved Regions of Human Papillomavirus (HPV) DNA Show Broad-spectrum Activity Against High-risk Genotypes*James Bashkin*^1,2^, Terri Edwards^2^, Kevin Koeller^1^, Terri Edwards^2^, Urszula Slomczynska^1^, Chris Fisher^21^University of Missouri-St. Louis, St. Louis, MO, United States; ^2^Nanovir, Kalamazoo, MI, United States  121.Synthesis and Biological Studies of Mutagenic Ribonucleoside Analogues as Potential Inducers of Error Catastrophe of Riboviruses*María-José Camarasa*^1^, Ana San-Félix^1^, M. Teresa Peromingo^1^, Mercedes Dávila^2^, Ana I. De Avila^2^, Rubén Agudo^2^, Esteban Domingo^21^Instituto De Química Médica (CSIC), Madrid, Spain; ^2^Centro De Biología Molecular "Severo Ochoa" (CSIC), Madrid, Spain  122.Antiflogistics as Viral Inhibitors*Georgy Danilenko*^1^, Svitlana Rybalko^2^, Tatiana Bukhtiarova^3^, Valentina Danilenko^3^, Svitlana Guzhova^1^, Victor Lozitsky^41^institute Organic Chemistry, Kyiv, Ukraine; ^2^Institute Epidemiology, Kyiv, Ukraine; ^3^Institute Pharmacology, Kyiv, Ukraine; ^4^Institute Pharmacology, Kyiv, Ukraine; ^5^Institute Organic Chemistry, Kyiv, Ukraine; ^6^Anti-Plague Institute, Odessa, Ukraine  123.Synthesis, Antiviral Activity, and Cytotoxicity of Some Novel 2-Phenyl-3-Disubstituted Quinazolin-4(3H)-ones*Periyasamy Selvam*^1^, Julie M. Breitenbach^2^, Katherine Z. Borysko^2^, John C. Drach^21^Amrita School of Pharmacy, AIMS Campus, Elamakkara, Kochi-682026, India, Kochi, India; ^2^School of Dentistry and College of Pharmacy, University of Michigan, Ann Arbor, MI, United States  124.Expression of Infectious Bursal Disease Virus (IBDV) Polyprotein and VP4 Protease*Phillia Vukea*, Alain Boulange, Theresa CoetzerUniversity of Kwa-Zulu-Natal, Pietermaritzburg, South Africa  125.Synthesis and SAR of 9-Arylpurines As Novel Inhibitors of Enterovirus Replication*Leire Aguado*^1^, Hendrik Jan Thibaut^2^, María-José Camarasa^1^, Johan Neyts^2^, María-Jesús Pérez-Pérez^11^Instituto De Química Médica (CSIC), 28006 Madrid, Spain; ^2^Rega Institute For Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium  126.HIT QSAR Study of Antivirals' Bioavailability*Anatoly Artemenko*^1^, Eugene Muratov^1,2^, Victor Kuz'min^1^, Maxim Kulinskij^1^, Irina Borisuk^1^, Nikolay Golovenko^1^, Alexander Tropsha^21^A.V. Bogatsky Physical-Chemical Institut, Odessa, Ukraine; ^2^University of Nort Carolina, Chapel Hill, NC, United States  127.Synthesis and Evaluation of Novel Acyclovir Phosphoramidates as Anti-HIV Agents*Davide Carta*^1^, Christopher Mcguigan^1^, Leonid Margolis^2^, Jan Balzarini^31^Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; ^2^Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States; ^3^Rega Institute For Medical Research, Leuven, Belgium  128.Design, Synthesis and SAR of New Potent HIV-1 RT Inhibitors*Alba Chimirri*^1^, Erik De Clercq^2^, Giovanni Maga^3^, Patrizia Logoteta^1^, Stefania Ferro^1^, Laura De Luca^1^, Nunzio Iraci^1^, Christophe Pannecouque^2^, Annamaria Monforte^11^University, Messina, Italy; ^2^Katholieke Universiteit, Leuven, Belgium; ^3^Istituto Di Genetica Molecolare IGM-CNR, Pavia, Italy  129.The Application of Phosphoramidate Protide Technology to Acyclovir Confers Novel Anti-HIV Inhibition*Marco Derudas*^1^, Christopher Mcguigan^1^, Andrea Brancale^1^, Leonid Margolis^2^, Jan Balzarini^31^Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; ^2^Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States; ^3^Rega Institute For Medical Research, Leuven, Belgium  130.Design, Synthesis, and Biological Evaluation of Novel Fluoro Derivatives of BCNA*Marco Derudas*^1^, Maurizio Quintiliani^1^, Christopher Mcguigan^1^, Andrea Brancale^1^, Geoffrey Henson^2^, Jan Balzarini^31^Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; ^2^Inibitex Inc., Alpharetta, GA, United States; ^3^Rega Institute For Medical Research, Leuven, Belgium  131.4,4-Disubstituted Cyclohexylamine based CCR5 Chemokine Receptor Antagonists as Anti-HIV-1 Agents*Maosheng Duan*, Wieslaw Kazmierski, Christopher Aquino, Rob Ferris, Terry Kenakin, Chris Watson, Pat WheelanInfectious Disease Center For Excellence In Drug Discovery, Glaxosmithkline, Research Triangle Park, NC, United States  132.Macrocyclic Polyamines Targeting the Cellular HIV Co-Receptors, CXCR4 and CCR5.*Sunil Hamal*^1^, Li Cui^1^, Bell Thomas^1^, Aquaro Stefano^2^, Dana Huskens^3^, Dominique Schols^31^Department of Chemistry, University of Nevada, Reno, NV, United States; ^2^Department of Experimental Medicine and Biochemical Sciences, University of Rome 'Tor Vergata', Rome, Italy; ^3^Rega Institute For Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium  133.Synthesis and Antiviral Activity of Substituted Uracils*Alexander Ivanov*^1^, Vera Tunitskaya^1^, Olga Smirnova^1^, Robert W. Buckheit, Jr.^2^, Katherine Seley-Radtke^3^, Alexander Ozerov^4^, Mikhail Novikov^41^Engelhardt Institute of Molecular Biology, Moscow, Russia; ^2^University of Maryland, Baltimore County, Baltimore, MD, United States; ^3^imquest Biosciences, Inc., Frederick, MD, United States; ^4^Volgograd State Medical University, Volgograd, Russia  134.Synthesis and Biological Evaluation of Acyclic Nucleotide Analogues of Bicyclic Pyrimidine Bases*Zlatko Janeba*^1^, Antonín Holý^1^, Robert Snoeck^2^, Graciela Andrei^2^, Eric De Clercq^2^, Jan Balzarini^21^Institute of Organic Chemistry and Biochemistry AS CR, Prague, Czech Republic; ^2^Rega Institute For Medical Research, Leuven, Belgium  135.HIV-1 Gag Matrix Protein Fragments and Polyacid Conjugates Designed for the HIV Inhibition*E. Karaseva*, A. Serbin, I. Rodionov, A. Vasiliev, V. Abramov, O. AlikhanovaHealth RDF, Moscow, Russia  136.CXCR4 Antagonists: A New Generation of Configurationally Restricted Bis-Azamacrocyclic Compounds*Abid Khan*^1^, Gary Nicholson^1^, Graeme Mcrobbie^1^, John Greenman^4^, Christophe Pannecouque^2^, Dirk Daelemans^2^, Dominique Schols^2^, Erik De Clercq^2^, Timothy J. Hubin^3^, Stephen J. Archibald^11^Department of Chemistry, University of Hull, Hull, United Kingdom; ^2^Rega Institute For Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium; ^3^Department of Chemistry and Physics, Southwestern Oklahoma State University, Weatherford, OK, United States; ^4^Centre For Medical Research, University of Hull, Hull, United Kingdom  137.West Nile Virus Helicase: Homology Modeling and Docking Studies*Mohammed Khedr*, Andrea BrancaleCardiff University, Welsh School of Pharmacy, Cardiff, United Kingdom  138.Nucleoside Phosphonate Analogues Modified by Lipophilic Cage Moiety as Potential Antiviral Agents.*Yuri Klimochkin*^1^, Marina Leonova^1^, Alexander Reznikov^1^, Andrey Shiraev^1^, Eugene Golovin^1^, Eugene Belanov^21^Samara State Technical University, Samara, Russia; ^2^FSRI SRC "Vector", Novosibirsk, Russia  139.Antiviral Activity of New Derivatives of CAGE Compounds*Yuri Klimochkin*^1^, Vitalij Osyanin^1^, Pavel Krasnikov^1^, Marina Leonova^1^, Eugene Golovin^1^, Sergey Balakhnin^2^, Eugene Belanov^21^Samara State Technical University, Samara, Russia; ^2^FSRI SRC "Vector", Novosibirsk, Russia  140.Antiviral Activity of Tetrahydro-2(1H)-Pyrimidinones and Related Compounds: Classification SAR Study*V. Kuz'min*^1^, E. Muratov^1,2^, A. Artemenko^1^, D. Sidzhakova^3^, A. Galabov^31^A.V. Bogatsky Physical-Chemical Institute NASU, Odessa, Ukraine; ^2^University of Nort Carolina, Chapel Hill, NC, USA; ^3^S. Angeloff Institute of Microbiology BAS, Sofia, Bulgaria  141.Cyclosaligenyl-Di-D4TMP: Highly Loaded Cyclosal-Pronucleotides that Release Two Equivalents of Nucleotides and Leaving One Masking Unit*Chris Meier*^1^, Nicolas Gisch^1^, Ducho Christian^1^, Balzarini Jan^21^Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany; ^2^Rega Institute For Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium  142.Computer-aided Drug Design of Novel Anti-Coxsackievirus B3 Nancy Agents By Means of HIT QSAR*E. Muratov*^1^, E. Varlamova^1^, V. Kuz'min^1^, A. Artemenko^1^, A. Kuz'mina^2^, A. Tropsha^3^, V. Makarov^4^, O. Riabova^4^, P. Wutzler^5^, M. Schmidtke^51^A.V. Bogatsky Physical-Chemical Institute NASU, Odessa, Ukraine; ^2^I.I. Mechnikov Odessa National Medical University, Odessa, Ukraine; ^3^University of North Carolina, Chapel Hill, NC, USA; ^4^Research Center For Antibiotics, Moscow, Russia; ^5^Institute of Virology and Antiviral Therapy, F. Schiller University, Jena, Germany  143.A Heterocyclic Molecule with Significant Activity against Dengue Virus*Vasu Nair*^1^, Guochen Chi^1^, Qingning Shu^1^, Justin Julander^2^, Donald Smee^21^University of Georgia, Athens, GA, USA; ^2^Utah State University, Logan, UT, USA  144.Synthesis and Properties of Cyclosal-phosphatetriesters of Fluorescent Bicyclic Nucleoside Analogues (BCNAS)Florian Pertenbreiter, Chris MeierOrganic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany  145.Anti-H5N1 Influenza Virus Activity of Carbocyclic Cytosine Nucleosides*J.R. Rao*^1^, A.K. Jha^1^, A. Sharon^1^, C.W. Day^2^, D.L. Bernard^2^, D.F. Smee^2^, C.K. Chu^11^University of Georgia, College of Pharmacy, Athens, GA, USA; ^2^Utah State University Institute For Antiviral Research, Logan, UT, USA  146.Synthesis of CADA Analog Pro-drugs Designed as Novel Down-Modulators of the CD4 Receptor*Emily Scarbrough*^1^, Sreenivasa Anugu^1^, Kurt Vermeire^2^, Dominique Schols^2^, Thomas Bell^11^Department of Chemistry, University of Nevada, Reno, NV, USA; ^2^Rega Institute For Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium  147.Bioreversible Protection of Nucleosidediphosphates---Synthesis and Properties*Tilmann Schulz*^1^, Henning J. Jessen^1^, Jan Balzarini^2^, Chris Meier^11^Institue of Organic Chemistry, Department of Chemistry, Faculty of Science, University of Hamburg, Martin-Luther-King Platz 6, D-20146, Hamburg, Germany; ^2^Rega Institute For Medical Research, Katholieke Universiteit Leuven, Minderbroederstraat 10, B-3000, Leuven, Belgium  148.Multivalent Synthetic Lectin Polymers against HIV*Julie Jay*^1^, Bonnie Lai^2^, Patrick Kiser^11^University of Utah, Department of Bioengineering, Salt Lake City, UT, USA; ^2^Duke University, Department of Biomedical Engineering, Durham, NC, USA  149.Induction of HIV-1 Gene Expression in Human Monocytic Cells by the Failed Microbicide Carrageenan Occurs through Activation of Toll-like Receptor 4 (TLR4)*Shawn Keogan*, Vanessa Pirrone, Shendra Passic, Brian Wigdahl, Fred KrebsDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA  150.Sevi and Semen Impair the Anti-HIV-1 Activity of Drugs and Microbicides*Kim Kyeong-Ae*^1^, Shibo Jiang^2^, Frank Kirchhoff^1^, Jan Muench^11^Institiute of Virology, Ulm, Germany; ^2^New York Blood Center, New York, NY, USA  151.Nonoxynol-9 (N-9), After Repeated Applications, Does Not Result in Cumulative Damage to the Murine Cervicovaginal Epithelium*Karissa Lozenski*^1^, Tina Kish-Catalone^2^, Brian Wigdahl^1^, Fred Krebs^11^Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA; ^2^Department of Natural Sciences, Desales University, Center Valley, PA, USA  152.Resistance Developed against Alamethicin an Antimicrobial Peptide in *Enterococcus faecalis* is Directly Proportional to its ConcentrationJitender Mehla, S.K., SoodNational Dairy Research Institute, Karnal, India  153.Using the CONRAD Testing Algorithm to Evaluate the Cytotoxicity and Anti-HIV-1 Activity of Candidate Microbicide Compounds*Shendra Passic*^1^, Vanessa Pirrone^1^, Brian Wigdahl^1^, Gustavo Doncel^2^, Fred Krebs^11^Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA; ^2^CONRAD, Arlington, VA, USA  154.Clinical Failures of Select Polyanionic Microbicide Candidates may be Predicted by *In Vitro* Enhancement of HIV-1 Infection*Vanessa Pirrone*, Shendra Passic, Brian Wigdahl, Fred KrebsDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA  155.A Macromolecular Basis for Microbicides Dual Protecting against HIV and Cytomegalovirus Infection*A. Serbin*^1^, E. Karaseva^1^, Y. Egorov^1^, I. Dunaeva^1^, M. Pavlova^2^, A. Kushch^21^Biomodulators RC, Health RDF, Moscow, Russia; ^2^D.I. Ivanovski Res. Inst. of Virology, RAMS, Moscow, Russia  156.CADA---A Potential Anti-HIV Microbicide that Specifically Targets the Cellular CD4 Receptor*Kurt Vermeire*^1^, Thomas Bell^2^, Roger Le Grand^3^, Joachim Brouwers^4^, Patrick Augustijns^4^, Dominique Schols^11^Rega Institute For Medical Research, K.U. Leuven, Leuven, Belgium; ^2^Department of Chemistry, University of Nevada, Reno, NV, USA; ^3^Service De Neurovirologie, Fontenay-Aux-Roses, France; ^4^Laboratory For Pharmacotechnology and Biopharmacy, K.U. Leuven, Leuven, Belgium  157.The Development of HIV-1 NCp7 Inhibitors as Components in Combination Topical Microbicides*Karen Watson*, Kathleen Powers, Lu Yang, Tracy Hartman, Robert W. Buckheit, Jr.ImQuest BioSciences, Inc., Frederick, MD, USA  158.Development of a Long Lasting Combination Microbicide Product Consisting of Highly Potent Compounds Exhibiting Multiple Mechanisms of Action*Karen Watson*, Lu Yang, Kathleen Powers, Joseph Kurczewski, Tracy Hartman, Robert Buckheit, Jr.ImQuest BioSciences, Inc., Frederick, MD, USA  **Wednesday, May 6, 2009**  **Prusoff Young Investigator Award Lecture**Mediterranean East  159.Presentation of AwardAmy Patick, Ph.D.President, ISAR  160.Viral Kinases as Targets for Antiviral TherapyMark Prichard, Ph.D.University of Alabama School of Medicine, Birmingham, AL, USA  **Oral Session 4: Herpesviruses And Poxviruses**Chairs: Rhonda Cardin, Ph.D. and Mark Prichard, Ph.D.Mediterranean East08:45--11:30   08:45161.Inhibition of Herpesvirus Replication with 5-Iodo-4′-Thio-2′-DeoxyuridineMark Prichard^1^, Debra Quenelle^1^, Caroll Hartline^1^, Emma Harden^1^, Geraldine Jefferson^1^, Samuel Frederick^1^, Terri Rice^1^, Deborah Collins^1^, Kamal Tiwari^2^, Joseph Maddry^2^, Richard Whitley^1^, John Secrist^2^, *Earl Kern*^11^University of Alabama School of Medicine, Birmingham, AL, USA; ^2^Southern Research Institute, Birmingham, AL, USA   09:00162.Selection and Characterization of (*S*)-1-\[3-Hydroxy-2-(Phosphonomethoxypropyl)-2,6-Diaminopurine \[HPMPDAP\] Resistant Camelpox Viruses*Sophie Duraffour*^1^, Robert Snoeck^1^, Pierre Fiten^2^, Ghislain Opdenakker^2^, Graciela Andrei^11^Laboratory of Virology, Rega Institute, Leuven, Belgium; ^2^Laboratory of Immunobiology, Rega Institute, Leuven, Belgium   09:15163.Effects of Anti-Human Papillomavirus (HPV) Disease Agents on HPV Episome Levels *In Vitro*: Cidofovir, Podophyllotoxin, and Pyrrole-imidazole Polyamides*Terri Edwards*^1^, Kevin Koeller^2^, James Bashkin^1,2^, Chris Fisher^11^Nanovir, Kalamazoo, MI, USA; ^2^University of Missouri-St. Louis, St. Louis, MO, USA   09:30Break   09:50164.Invitation to the 23rd ICAR, San Francisco, CA, USAChris McGuigan, Ph.D.Chair, ICAR Conference Committee   10:00ISAR Business Meeting   10:15165.Identification of the Type of Cells Responsible for Transfer of Herpes Simplex Virus (HSV) and Vaccinia Virus (VACV) Infection to Epithelial Cells Grown in 3D*Graciela Andrei*^1^, Dirk Daelemans^1^, Els Vanstreels^1^, Sophie Duraffour^1^, Joos Van Den Oord^2^, Erik De Clercq^1^, Robert Snoeck^11^Rega Institute For Medical Research, K.U. Leuven, Leuven, Belgium; ^2^Laboratory of Morphology and Molecular Pathology, K.U. Leuven, Leuven, Belgium   10:30166.Drug Resistance Mutations in HSV-1 UL5 Selected Using a Helicase-Primase Inhibitor: Frequency and Effects on Virus Growth and Pathogenicity*Subhajit Biswas*, Soumi Sukla, Hugh J FieldDepartment of Veterinary Medicine, University of Cambridge, Cambridge, CB3 0ES, United Kingdom   10:45167.Murine Model of Recurrent Vaginal HSV-2 Shedding and Effect of Acyclovir*Rhonda Cardin*, Nicholas Farley, Fernando Bravo, Julie Earwood, Nancy Sawtell, David BernsteinCincinnati Children\'s Hosp, Med. Center, Cincinnati, OH, USA   11:00168.Activation of Cyclopropavir Involves Unique Phosphorylation by Guanylate Kinase*Brian G. Gentry*^1^, Chengwei Li^2^, John C. Drach^1^, Jiri Zemlicka^21^University of Michigan, Ann Arbor, MI, USA; ^2^Wayne State University, Detroit, MI, USA   11:15169.EBNA1---A Virally Encoded Protein Binds Cellular Host Promoters in a Unique Sequence and Directly Interferes with Cellular Gene Expression: Implications for Genomics Approaches in Drug Design*Allon Canaan*, Vincent Schulz, Milind Mahajan, Alexander Urban, Sherman WeissmanYale University School of Medicine, New Haven, CT, USA  **Oral Session 5: Respiratory Viruses, Emerging Viruses And Biodefense**Chairs: Dale Barnhard, Ph.D. and Brian Gowen, Ph.D.Mediterranean East13:00--16:00   13:00170.Plenary: Filoviral Minigenome Systems and iVLPs as Tools for Antiviral Research*Stephan Becker*, Ph.D.University of Marburg, Marburg, Germany   13:30171.Identification and Mechanistic Studies on a Novel Class of Influenza Virus Fusion Inhibitors*Evelien Vanderlinden*^1^, Nesrin Cesur^2^, Zafer Cesur^2^, Fusun Goktas^2^, Mathy Froeyen^1^, Charles Russell^3^, Lieve Naesens^11^Rega Institute For Medical Research, Leuven, Belgium; ^2^Istanbul University, Faculty of Pharmacy, Istanbul, Turkey; ^3^St. Jude Children\'s Research Hospital, Memphis, TN, USA   13:45172.Novel Broad-spectrum Biopharmaceuticals: From HIV-1 to Pandemic Influenza a Virus*François Jean*^1^, Vesna Posarac^1^, Peter Cheung^2^, Martine Boutin^1^, Heather Braybrook^1^, Richard Harrigan^21^Department of Microbiology & Immunology, University of British Columbia, Vancouver, BC, Canada; ^2^B.C. Centre For Excellence In HIV/AIDS, St. Paul\'s Hospital, Vancouver, BC, Canada   14:00173.Recruitment of the TSG101/ESCRT-I Machinery in Host Cells by Influenza Virus: Implications for Broad Spectrum Therapy*Leyla Diaz*, Josephine Cassella, Aurelio Bonavia, Roxanne Duan, David Santos, Zena Fesseha, Michael Goldblatt, Michael KinchFunctional Genetics, Inc., Gaithersburg, MD, USA   14:15174.Role of Na Mutations Conferring Resistance to NA Inhibitors on Viral Fitness and Pathogenicity in A/Turkey/15/06 (H5N1) Influenza Virus*Natalia A. Ilyushina*, Jon P. Seiler, Robert G. Webster, Elena A. GovorkovaSt. Jude Children\'s Research Hospital, Memphis, TN, USA   14:30175.*In-Vivo* Efficacy Evaluation of Vaccines against H5N1 Influenza VirusNutan MytleSouthern Research Institute, Birmingham, AL, USA   14:45176.Activity of Certain 5-Substituted-4′-Thio Pyrimindine Nucleosides against Orthopoxvirus InfectionsEarl Kern^1^, Mark Prichard^1^, *Debra Quenelle*^1^, Kathy Keith^1^, Kamal Tiwari^2^, Joseph Maddry^2^, John Secrist III^21^University of Alabama School of Medicine, Birmingham, AL, USA; ^2^Southern Research Institute, Birmingham, AL, USA   15:00177.Motor Unit Number Estimation as a Therapeutic Marker in Acute and Persistent West Nile Virus Infection In Hamsters*John D. Morrey*^1^, Venkatraman Siddharthan^1^, Hong Wang^1^, Neil E. Motter^1^, Jeffery O. Hall^1^, Robert D. Skinner^2^, Ramona T. Skirpstunas^11^Utah State University, Logan, UT, USA; ^2^University of Arkansas For Medical Sciences, Little Rock, AR, USA   15:15178.Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against Dengue Virus*Jinhong Chang*^1^, Lijuan Wang^1^, Dongling Ma^1^, Xiaodong Xu^2,3^, Wouter Schul^4^, Pei-Yong Shi^4^, Peter M. Mason^5^, Nigel Bourne^5^, Robert Moriarty^6^, Ju-Tao Guo^1^, Timothy M. Block^1,21^Drexel University College of Medicine, Doylestown, PA, USA; ^2^Institute For Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, PA, USA; ^3^Pharmabridge Inc., Doylestown, PA, USA; ^4^Novartis Institute For Tropical Diseases, Chromos, Singapore; ^5^University of Texas Medical Branch, Galveston, TX, USA; ^6^University of Illinois, Chicago, IL, USA   15:30179.Using The C57BL/6 and SKH1 Strains to Evaluate the Efficacy of CMX001 following Lethal Respiratory Infections with Ectromelia Virus*Scott Parker*^1^, Christina Oberle^1^, Ed Hembrador^1^, Jill Schriewer^1^, Geroge Painter^2^, Randall Lanier^21^Saint Louis University, St Louis, MO, USA; ^2^Chimerix Inc., Durham, NC, USA   15:45180.Novel 9-Arylpurines, as Selective Inhibitors of *In Vitro* Enterovirus Replication*Hendrik Jan Thibaut*^1^, Leire Aguado^2^, Lonneke Van Der Linden^3^, Armando De Palma^1^, María-José Camarasa^2^, Jan Balzarini^1^, Frank Van Kuppeveld^3^, María Jesús Pérez-Pérez^2^, Johan Neyts^11^Rega Institute For Medical Research, Kuleuven, Leuven, Belgium; ^2^Instituto De Química Médica (CSIC), Madrid, Spain; ^3^Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen Centre For Molecular Life Sciences, Nijmegen, Netherlands  **Shotgun Poster Presentations**Chairs: Robert W. Buckheit, Jr., Ph.D. and Chris McGuigan, Ph.D.Mediterranean East16:15--18:15  **Thursday, May 7, 2009**  **Oral Session 6: Mini-Symposium: Perspectives And Challenges In The Development Of Topical Microbicides**Chairs: Sharon Hillier, Ph.D. and Jim Turpin, Ph.D.Mediterranean East08:00--10:00   08:00181.A Microbicide Perspective: Past, Present, and Future*Sharon Hillier*, Ph.D.University of Pittsburgh, Pittsburgh, PA, USA   08:20182.Microbicide Product Development: What is a Microbicide?*Jim Turpin*DAIDS, NIAID, NIH, Bethesda, MD, USA   08:40183.Formulation of Compounds for Vaginal and Rectal Delivery*Patrick Kiser*, Ph.D.University of Utah, Salt Lake City, UT, USA   09:00184.Development of Microbicides with Broad Based Anti-infective Action*Betsy Herold*, M.D.The Albert Einstein University, Bronx, NY, USA   09:20185.The Microbicide Pipeline: Clinical Development Success and Failure*Joseph Romano*, Ph.D.International Partnership For Microbicides, Silver Spring, MD, USA   09:40Break  **Oral Session 7: Microbicides, Drug Design And Late Breaker Presentations**Chairs: Nick Kaludov, Ph.D. and Andrea Brancale, Ph.D.Mediterranean East10:00 a.m.--12:00   10:00186.Design of an Intravaginal Ring for Simultaneous Delivery of Antiretroviral Drugs*Todd Johnson*, Kavita Gupta, Patrick KiserUniversity of Utah, Department of Bioengineering, Salt Lake City, UT, USA   10:15187.Biophysical Mechanisms in Microbicide Pharmacokinetics*David Katz*, Marcus Henderson, Bonnie Lai, Anthony Geonnotti, Jennifer PetersDepartment of Biomedical Engineering, Duke University, Durham, NC, USA   10:30188.Virtual Reality Applications in Antiviral Drug Design*Nicola Zonta*, Andrea BrancaleWelsh School of Pharmacy, Cardiff, United Kingdom   10:45189.Identification of a Small-Molecule Antiviral with Broad-spectrum Application to Multiple, Lethal Virus Types*Abdul Yunus*^1^, Travis Warren^2^, Kelly Warfield^3^, Sven Enterlein^3^, Shaojing Chang^1^, Hanwen Mao^1^, Javad Aman^3^, Sina Bavari^2^, Michael Goldblatt^1^, Michael Kinch^11^Functional Genetics, Inc., Gaithersburg, MD, USA; ^2^United States Army Medical Research Instiute of Infectious Diseases, Fort Detrick, MD, USA; ^3^Integrated Biotherapeutics, Germantown, MD, USA   11:00Late Breaker Presentation   11:15Late Breaker Presentation   11:30Late Breaker Presentation   11:45Late Breaker Presentation
